Патогенетические основы одновременной коррекции эректильной дисфункции и расстройств мочеиспускания
Аннотация
Об авторах
В. В. ДаниловРоссия
А. В. Васильченко
Россия
Т. И. Данилова
Россия
В. В. Данилов
Россия
С. В. Беседин
Россия
Список литературы
1. Урофлоуметрия / Вишневский Е.Л., Пушкарь Д.Ю., Лоран О.Б. и др. М.: Печатный город, 2004. 220 с.
2. Behr-Roussel D., Gorny D., Mevel K. et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of ta-chyphylaxis // European Urology. 2005. Vol. 47, No. 1. P. 87-91.
3. Eardley I. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunc-tion: converting “non-responders” into “responders” // European urology. 2006. Vol. 50, No. 1. P. 31-33.
4. El-Sakka A.I. Lower urinary tract symptoms in patients with erectile dysfunc-tion: is there a vascular association? // European Urology. 2005. Vol. 48, No. 2. P. 319-325.
5. Hoesl C.E., Woll E.M., Burkart M., Altwein J.E. Erectile dysfunction is preva-lent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome // European Urology. 2005. Vol. 47, No. 4. P. 511-517.
6. Kaplan S.A., Gonzalez R., Ogiste J., Te A.E. Combination of an a1-blocker, al-fuzosin and a PDE5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms and sexual dysfunction // European Urol-ogy Supplements. 2006. Vol. 5, No. 2. P. 197-197.
7. Mirone V., Costa P., Damber J.-E. et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries // European Urology. 2005. Vol. 47, No. 6. P. 846-854.
8. Montorsi F., Briganti A., Saloni A. et al. Can Phosphodiesterase type 5 inhibitor cure erectile dysfunction? // European urology. - 2006. - Vol. 49, No. 6. P. 979-986.
9. Ng C.F., Wong Y.F., Wong H.M. et al. A prospective randomised crossover trial on the effect of vardenafil 10mg on blood pressure in patients with erectile dys-function who receive concomitant doxazosin gits for the treatment of benign prostatic hyperplasia // European Urology Supplements. 2008. Vol. 7, No. 2. P. 160.
10. Umul M., Altay B., Bademkiran F et al. Evaluating the relationship between lower urinary tract symptoms associated with bening proststic hyperplasia and erectile dysfunction: role of autonomic hyperactivity // European Urology Sup-plements. 2008. Vol. 7, No. 3. P. 160.
11. Zlotta A.R., Teillac P., Raynaud J.P., Schulman C.C. Evaluation of male sexual function in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride // European Urology. 2005. Vol. 48, No. 2. P. 269-276.
Рецензия
Для цитирования:
Данилов В.В., Васильченко А.В., Данилова Т.И., Данилов В.В., Беседин С.В. Патогенетические основы одновременной коррекции эректильной дисфункции и расстройств мочеиспускания. Тихоокеанский медицинский журнал. 2011;(1):36-40.
For citation:
Danilov V.V., Vasilchenko A.V., Danilova T.I., Danilov V.V., Besedin S.V. Pathogenetic fundamentals of simultaneous correction of erectile dysfunction and urination disorders. Pacific Medical Journal. 2011;(1):36-40. (In Russ.)